| Patients’characteristics . | . | All patients (n = 311) . | Right-sided (n = 160) . | Left-sided (n = 151) . | |||
|---|---|---|---|---|---|---|---|
| . | n . | % . | n . | % . | n . | % . | |
| Age | <55 | 174 | 55.9% | 87 | 54.4% | 87 | 57.6% |
| ≥55 | 137 | 44.1% | 73 | 45.6% | 64 | 42.4% | |
| Clinical stage (UICC 7th) | 0 | 48 | 15.4% | 21 | 13.1% | 27 | 17.9% |
| I | 164 | 52.7% | 82 | 51.3% | 82 | 54.3% | |
| II | 49 | 15.8% | 27 | 16.9% | 22 | 14.6% | |
| III | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Unknown | 33 | 10.6% | 21 | 13.1% | 12 | 7.9% | |
| T stage | Tis | 19 | 6.1% | 7 | 4.4% | 12 | 7.9% |
| 0 | 23 | 7.4% | 14 | 8.8% | 9 | 6% | |
| 1 | 190 | 61.1% | 92 | 57.5% | 98 | 64.9% | |
| 2 | 37 | 11.9% | 22 | 13.8% | 15 | 9.9% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 41 | 13.2% | 24 | 15% | 17 | 11.3% | |
| N stage | 0 | 237 | 76.2% | 116 | 72.5% | 121 | 80.1% |
| 1 | 36 | 11.6% | 21 | 13.1% | 15 | 9.9% | |
| 2 | 4 | 1.3% | 2 | 1.3% | 2 | 1.3% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 33 | 10.6% | 20 | 12.5% | 13 | 8.6% | |
| BMI | <25 | 248 | 79.7% | 132 | 82.5% | 116 | 76.8% |
| 25≤ | 63 | 20.3% | 28 | 17.5% | 35 | 23.2% | |
| Smoking history | No | 192 | 61.7% | 99 | 61.9% | 93 | 61.6% |
| Yes | 22 | 7.1% | 8 | 5% | 14 | 9.3% | |
| NA | 97 | 31.2% | 53 | 33.1% | 44 | 29.1% | |
| Hypertension | No | 242 | 77.8% | 127 | 79.4% | 115 | 76.2% |
| Yes | 69 | 22.2% | 33 | 20.6% | 36 | 23.8% | |
| Diabetes | No | 284 | 91.3% | 146 | 91.3% | 138 | 91.4% |
| Yes | 27 | 8.7% | 14 | 8.8% | 13 | 8.6% | |
| Dyslipidemia | No | 258 | 83% | 131 | 81.9% | 127 | 84.1% |
| Yes | 53 | 17% | 29 | 18.1% | 24 | 15.9% | |
| Chemotherapy | No | 235 | 75.6% | 119 | 74.4% | 116 | 76.8% |
| Yes | 76 | 24.4% | 41 | 25.6% | 35 | 23.2% | |
| Hormone therapy | No | 127 | 40.8% | 70 | 43.8% | 57 | 37.7% |
| Yes | 184 | 59.2% | 90 | 56.3% | 94 | 62.3% | |
| Painkiller | No | 294 | 94.5% | 151 | 94.4% | 143 | 94.7% |
| Yes | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Anthracycline antitumor drug | No | 256 | 82.3% | 129 | 80.6% | 127 | 84.1% |
| Yes | 55 | 17.7% | 31 | 19.4% | 24 | 15.9% | |
| Herceptin | No | 295 | 94.9% | 151 | 94.4% | 144 | 95.4% |
| Yes | 13 | 4.2% | 7 | 4.4% | 6 | 4% | |
| NA | 3 | 1% | 2 | 1.3% | 1 | 0.7% | |
| Coronary artery calcification | No | 303 | 97.4% | 157 | 98.1% | 146 | 96.7% |
| Yes | 8 | 2.6% | 3 | 1.9% | 5 | 3.3% | |
| Total irradiation dose | 50 Gy | 213 | 68.5% | 112 | 70% | 100 | 66.2% |
| 60 Gy | 97 | 31.2% | 47 | 29.4% | 51 | 33.8% | |
| 52.56 Gy | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Mean dose of whole heart | Median (range) | 3.15 Gy (0.86–10.85) | |||||
| Mean dose of left ventricle | Median (range) | 5.08 Gy (1.26–14.19) | |||||
| Mean dose of left anterior descending coronary artery | Median (range) | 29.94 Gy (2.23–53.33) | |||||
| Patients’characteristics . | . | All patients (n = 311) . | Right-sided (n = 160) . | Left-sided (n = 151) . | |||
|---|---|---|---|---|---|---|---|
| . | n . | % . | n . | % . | n . | % . | |
| Age | <55 | 174 | 55.9% | 87 | 54.4% | 87 | 57.6% |
| ≥55 | 137 | 44.1% | 73 | 45.6% | 64 | 42.4% | |
| Clinical stage (UICC 7th) | 0 | 48 | 15.4% | 21 | 13.1% | 27 | 17.9% |
| I | 164 | 52.7% | 82 | 51.3% | 82 | 54.3% | |
| II | 49 | 15.8% | 27 | 16.9% | 22 | 14.6% | |
| III | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Unknown | 33 | 10.6% | 21 | 13.1% | 12 | 7.9% | |
| T stage | Tis | 19 | 6.1% | 7 | 4.4% | 12 | 7.9% |
| 0 | 23 | 7.4% | 14 | 8.8% | 9 | 6% | |
| 1 | 190 | 61.1% | 92 | 57.5% | 98 | 64.9% | |
| 2 | 37 | 11.9% | 22 | 13.8% | 15 | 9.9% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 41 | 13.2% | 24 | 15% | 17 | 11.3% | |
| N stage | 0 | 237 | 76.2% | 116 | 72.5% | 121 | 80.1% |
| 1 | 36 | 11.6% | 21 | 13.1% | 15 | 9.9% | |
| 2 | 4 | 1.3% | 2 | 1.3% | 2 | 1.3% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 33 | 10.6% | 20 | 12.5% | 13 | 8.6% | |
| BMI | <25 | 248 | 79.7% | 132 | 82.5% | 116 | 76.8% |
| 25≤ | 63 | 20.3% | 28 | 17.5% | 35 | 23.2% | |
| Smoking history | No | 192 | 61.7% | 99 | 61.9% | 93 | 61.6% |
| Yes | 22 | 7.1% | 8 | 5% | 14 | 9.3% | |
| NA | 97 | 31.2% | 53 | 33.1% | 44 | 29.1% | |
| Hypertension | No | 242 | 77.8% | 127 | 79.4% | 115 | 76.2% |
| Yes | 69 | 22.2% | 33 | 20.6% | 36 | 23.8% | |
| Diabetes | No | 284 | 91.3% | 146 | 91.3% | 138 | 91.4% |
| Yes | 27 | 8.7% | 14 | 8.8% | 13 | 8.6% | |
| Dyslipidemia | No | 258 | 83% | 131 | 81.9% | 127 | 84.1% |
| Yes | 53 | 17% | 29 | 18.1% | 24 | 15.9% | |
| Chemotherapy | No | 235 | 75.6% | 119 | 74.4% | 116 | 76.8% |
| Yes | 76 | 24.4% | 41 | 25.6% | 35 | 23.2% | |
| Hormone therapy | No | 127 | 40.8% | 70 | 43.8% | 57 | 37.7% |
| Yes | 184 | 59.2% | 90 | 56.3% | 94 | 62.3% | |
| Painkiller | No | 294 | 94.5% | 151 | 94.4% | 143 | 94.7% |
| Yes | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Anthracycline antitumor drug | No | 256 | 82.3% | 129 | 80.6% | 127 | 84.1% |
| Yes | 55 | 17.7% | 31 | 19.4% | 24 | 15.9% | |
| Herceptin | No | 295 | 94.9% | 151 | 94.4% | 144 | 95.4% |
| Yes | 13 | 4.2% | 7 | 4.4% | 6 | 4% | |
| NA | 3 | 1% | 2 | 1.3% | 1 | 0.7% | |
| Coronary artery calcification | No | 303 | 97.4% | 157 | 98.1% | 146 | 96.7% |
| Yes | 8 | 2.6% | 3 | 1.9% | 5 | 3.3% | |
| Total irradiation dose | 50 Gy | 213 | 68.5% | 112 | 70% | 100 | 66.2% |
| 60 Gy | 97 | 31.2% | 47 | 29.4% | 51 | 33.8% | |
| 52.56 Gy | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Mean dose of whole heart | Median (range) | 3.15 Gy (0.86–10.85) | |||||
| Mean dose of left ventricle | Median (range) | 5.08 Gy (1.26–14.19) | |||||
| Mean dose of left anterior descending coronary artery | Median (range) | 29.94 Gy (2.23–53.33) | |||||
| Patients’characteristics . | . | All patients (n = 311) . | Right-sided (n = 160) . | Left-sided (n = 151) . | |||
|---|---|---|---|---|---|---|---|
| . | n . | % . | n . | % . | n . | % . | |
| Age | <55 | 174 | 55.9% | 87 | 54.4% | 87 | 57.6% |
| ≥55 | 137 | 44.1% | 73 | 45.6% | 64 | 42.4% | |
| Clinical stage (UICC 7th) | 0 | 48 | 15.4% | 21 | 13.1% | 27 | 17.9% |
| I | 164 | 52.7% | 82 | 51.3% | 82 | 54.3% | |
| II | 49 | 15.8% | 27 | 16.9% | 22 | 14.6% | |
| III | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Unknown | 33 | 10.6% | 21 | 13.1% | 12 | 7.9% | |
| T stage | Tis | 19 | 6.1% | 7 | 4.4% | 12 | 7.9% |
| 0 | 23 | 7.4% | 14 | 8.8% | 9 | 6% | |
| 1 | 190 | 61.1% | 92 | 57.5% | 98 | 64.9% | |
| 2 | 37 | 11.9% | 22 | 13.8% | 15 | 9.9% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 41 | 13.2% | 24 | 15% | 17 | 11.3% | |
| N stage | 0 | 237 | 76.2% | 116 | 72.5% | 121 | 80.1% |
| 1 | 36 | 11.6% | 21 | 13.1% | 15 | 9.9% | |
| 2 | 4 | 1.3% | 2 | 1.3% | 2 | 1.3% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 33 | 10.6% | 20 | 12.5% | 13 | 8.6% | |
| BMI | <25 | 248 | 79.7% | 132 | 82.5% | 116 | 76.8% |
| 25≤ | 63 | 20.3% | 28 | 17.5% | 35 | 23.2% | |
| Smoking history | No | 192 | 61.7% | 99 | 61.9% | 93 | 61.6% |
| Yes | 22 | 7.1% | 8 | 5% | 14 | 9.3% | |
| NA | 97 | 31.2% | 53 | 33.1% | 44 | 29.1% | |
| Hypertension | No | 242 | 77.8% | 127 | 79.4% | 115 | 76.2% |
| Yes | 69 | 22.2% | 33 | 20.6% | 36 | 23.8% | |
| Diabetes | No | 284 | 91.3% | 146 | 91.3% | 138 | 91.4% |
| Yes | 27 | 8.7% | 14 | 8.8% | 13 | 8.6% | |
| Dyslipidemia | No | 258 | 83% | 131 | 81.9% | 127 | 84.1% |
| Yes | 53 | 17% | 29 | 18.1% | 24 | 15.9% | |
| Chemotherapy | No | 235 | 75.6% | 119 | 74.4% | 116 | 76.8% |
| Yes | 76 | 24.4% | 41 | 25.6% | 35 | 23.2% | |
| Hormone therapy | No | 127 | 40.8% | 70 | 43.8% | 57 | 37.7% |
| Yes | 184 | 59.2% | 90 | 56.3% | 94 | 62.3% | |
| Painkiller | No | 294 | 94.5% | 151 | 94.4% | 143 | 94.7% |
| Yes | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Anthracycline antitumor drug | No | 256 | 82.3% | 129 | 80.6% | 127 | 84.1% |
| Yes | 55 | 17.7% | 31 | 19.4% | 24 | 15.9% | |
| Herceptin | No | 295 | 94.9% | 151 | 94.4% | 144 | 95.4% |
| Yes | 13 | 4.2% | 7 | 4.4% | 6 | 4% | |
| NA | 3 | 1% | 2 | 1.3% | 1 | 0.7% | |
| Coronary artery calcification | No | 303 | 97.4% | 157 | 98.1% | 146 | 96.7% |
| Yes | 8 | 2.6% | 3 | 1.9% | 5 | 3.3% | |
| Total irradiation dose | 50 Gy | 213 | 68.5% | 112 | 70% | 100 | 66.2% |
| 60 Gy | 97 | 31.2% | 47 | 29.4% | 51 | 33.8% | |
| 52.56 Gy | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Mean dose of whole heart | Median (range) | 3.15 Gy (0.86–10.85) | |||||
| Mean dose of left ventricle | Median (range) | 5.08 Gy (1.26–14.19) | |||||
| Mean dose of left anterior descending coronary artery | Median (range) | 29.94 Gy (2.23–53.33) | |||||
| Patients’characteristics . | . | All patients (n = 311) . | Right-sided (n = 160) . | Left-sided (n = 151) . | |||
|---|---|---|---|---|---|---|---|
| . | n . | % . | n . | % . | n . | % . | |
| Age | <55 | 174 | 55.9% | 87 | 54.4% | 87 | 57.6% |
| ≥55 | 137 | 44.1% | 73 | 45.6% | 64 | 42.4% | |
| Clinical stage (UICC 7th) | 0 | 48 | 15.4% | 21 | 13.1% | 27 | 17.9% |
| I | 164 | 52.7% | 82 | 51.3% | 82 | 54.3% | |
| II | 49 | 15.8% | 27 | 16.9% | 22 | 14.6% | |
| III | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Unknown | 33 | 10.6% | 21 | 13.1% | 12 | 7.9% | |
| T stage | Tis | 19 | 6.1% | 7 | 4.4% | 12 | 7.9% |
| 0 | 23 | 7.4% | 14 | 8.8% | 9 | 6% | |
| 1 | 190 | 61.1% | 92 | 57.5% | 98 | 64.9% | |
| 2 | 37 | 11.9% | 22 | 13.8% | 15 | 9.9% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 41 | 13.2% | 24 | 15% | 17 | 11.3% | |
| N stage | 0 | 237 | 76.2% | 116 | 72.5% | 121 | 80.1% |
| 1 | 36 | 11.6% | 21 | 13.1% | 15 | 9.9% | |
| 2 | 4 | 1.3% | 2 | 1.3% | 2 | 1.3% | |
| 3 | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Unknown | 33 | 10.6% | 20 | 12.5% | 13 | 8.6% | |
| BMI | <25 | 248 | 79.7% | 132 | 82.5% | 116 | 76.8% |
| 25≤ | 63 | 20.3% | 28 | 17.5% | 35 | 23.2% | |
| Smoking history | No | 192 | 61.7% | 99 | 61.9% | 93 | 61.6% |
| Yes | 22 | 7.1% | 8 | 5% | 14 | 9.3% | |
| NA | 97 | 31.2% | 53 | 33.1% | 44 | 29.1% | |
| Hypertension | No | 242 | 77.8% | 127 | 79.4% | 115 | 76.2% |
| Yes | 69 | 22.2% | 33 | 20.6% | 36 | 23.8% | |
| Diabetes | No | 284 | 91.3% | 146 | 91.3% | 138 | 91.4% |
| Yes | 27 | 8.7% | 14 | 8.8% | 13 | 8.6% | |
| Dyslipidemia | No | 258 | 83% | 131 | 81.9% | 127 | 84.1% |
| Yes | 53 | 17% | 29 | 18.1% | 24 | 15.9% | |
| Chemotherapy | No | 235 | 75.6% | 119 | 74.4% | 116 | 76.8% |
| Yes | 76 | 24.4% | 41 | 25.6% | 35 | 23.2% | |
| Hormone therapy | No | 127 | 40.8% | 70 | 43.8% | 57 | 37.7% |
| Yes | 184 | 59.2% | 90 | 56.3% | 94 | 62.3% | |
| Painkiller | No | 294 | 94.5% | 151 | 94.4% | 143 | 94.7% |
| Yes | 17 | 5.5% | 9 | 5.6% | 8 | 5.3% | |
| Anthracycline antitumor drug | No | 256 | 82.3% | 129 | 80.6% | 127 | 84.1% |
| Yes | 55 | 17.7% | 31 | 19.4% | 24 | 15.9% | |
| Herceptin | No | 295 | 94.9% | 151 | 94.4% | 144 | 95.4% |
| Yes | 13 | 4.2% | 7 | 4.4% | 6 | 4% | |
| NA | 3 | 1% | 2 | 1.3% | 1 | 0.7% | |
| Coronary artery calcification | No | 303 | 97.4% | 157 | 98.1% | 146 | 96.7% |
| Yes | 8 | 2.6% | 3 | 1.9% | 5 | 3.3% | |
| Total irradiation dose | 50 Gy | 213 | 68.5% | 112 | 70% | 100 | 66.2% |
| 60 Gy | 97 | 31.2% | 47 | 29.4% | 51 | 33.8% | |
| 52.56 Gy | 1 | 0.3% | 1 | 0.6% | 0 | 0% | |
| Mean dose of whole heart | Median (range) | 3.15 Gy (0.86–10.85) | |||||
| Mean dose of left ventricle | Median (range) | 5.08 Gy (1.26–14.19) | |||||
| Mean dose of left anterior descending coronary artery | Median (range) | 29.94 Gy (2.23–53.33) | |||||
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
